Figures cited from named public press (XCath / Operation Robo Angel items retrieved 1 September 2026) and the published bioaccess® Panama country page. Press mention_n is not a bioaccess® claim that we ran this procedure. General information, not legal or regulatory advice. Confirm current MINSA, CNBI, and FDA rules with qualified advisers. We name only the facilities, operators, and sponsor those sources support. We do not invent Clínica Norte as the implant hospital. We do not invent a CRO the wires did not name. We do not claim Clínica Norte, XCath, or this procedure as a bioaccess® client program.
If you searched Clínica Norte Santiago Panama first-in-human, Clínica Norte CRO, XCath Iris Panama, or “go direct Clínica Norte,” you followed a clinic name that is genuinely in the public file. Clínica Norte in Santiago, Panama, is a real building. In the XCath wires it is the remote operator site. It is not the implant hospital. It is not a first-in-human medical-device CRO. It is not the operator of the MINSA file.
bioaccess®’s position is simple and it is not adversarial: the buildings are sites. The First-in-Human CRO still owns MINSA/CNBI, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package — plus the option to add Colombia or another Latin American country if Panama is not the only fit. Sponsors who skip the CRO and email either clinic still have to rebuild that stack. A press release that names a remote console does not become a CRO.
This page is the intercept for the Clínica Norte / remote-console query. The patient-side hospital intercept is already live: The Panama Clinic first-in-human (CMS 95513). Link it. Do not clone it. Do not move the implant to Santiago because the operator sat in Santiago.
What the press actually printed — two buildings, one patient
Device press writes the robot, the city, and the surgeons. It rarely writes the CRO. On the 1 September 2026 LATAM device FIH/EFS press sweep, Clínica Norte, Santiago, Panama, is rank 7, mention_n=4 — always paired with The Panama Clinic. Example URLs the ranking actually used:
- XCath / Business Wire, 19 March 2026 — world’s first remote robotic intervention in a stroke patient (Iris; Operation Robo Angel). The ranking log and matching trade read the same split: patient at The Panama Clinic; remote operator at Clínica Norte, Santiago.
- NeuroNews, 25 March 2026 — Vitor Pereira led the procedure from Clinica Norte in Santiago, Panama — more than 200 km from the patient in Panama City. Bedside: Anastasio Ameijeiras Sibauste (The Panama Clinic). The patient was transferred to The Panama Clinic and treated there. We will not rewrite that to put the implant in Santiago.
- Matching MassDevice and Fierce Biotech rewrites name both buildings. None of them name a CRO.
That is how a founder googles “Clínica Norte first-in-human” and concludes Santiago was the implant hospital. The wires do not say that. The patient was at The Panama Clinic. Clínica Norte held the remote console. We will not invent a CRO. We will not claim bioaccess® ran Operation Robo Angel. Named bioaccess® work at The Panama Clinic (Axoft, Newrotex) stays on the hospital intercept — not this XCath page.
Clínica Norte is a remote site. The Panama Clinic is the bedside hospital. The CRO is the operator.
A Santiago, Panama clinic can host a remote console. A Panama City hospital can host the patient, the angiography suite, and the bedside team. That is necessary. Neither building, by appearing in an XCath wire, becomes MINSA/CNBI, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager.
What either site can typically do when a sponsor “goes direct”:
- Discuss investigator interest and whether a protocol can sit in an existing neurointerventional service.
- Share institutional ethics-committee calendars and hospital research rules.
- Quote visit, staffing, and local procedure costs for the role they will physically run (console vs bedside).
What neither site is built to own for an investigational device:
- MINSA and CNBI. The national device file is not a hallway conversation with a remote operator or a bedside neurosurgeon.
- Investigational import. Ethics letter, investigator’s brochure, and an importation permit — end-to-end work already described on the Panama pages. See importer of record for clinical trial devices in Latin America.
- Clinical trial insurance. Required. The Panama essay publishes a typical premium range of $5,000–$15,000 depending on device risk and enrollment; that is a published planning band, not a quote for this protocol.
- ISO 14155 monitoring, EDC, SAE reporting, and the TMF — including how a remote console and a bedside hospital are documented as one investigation.
- The 21 CFR 812.28 package. Eligibility is not clearance. A site MSA does not produce it.
- Multi-country optionality. If Panama enrollment or the indication later needs Colombia, El Salvador, Brazil, or another bioaccess® market, a single-clinic MSA will not stretch.
Going direct to Clínica Norte is how you confirm a console room. Going direct to The Panama Clinic is how you confirm a bedside room. Neither is how you open a first-in-human device investigation.
Site versus CRO
| Workstream | What the press actually assigned | What the CRO still owns |
|---|---|---|
| Remote console | Clínica Norte, Santiago, Panama — Vitor Mendes Pereira (University of Toronto) in the NeuroNews rewrite | Protocol fit, training, device accountability across both rooms |
| Patient / implant hospital | The Panama Clinic, Panama City — bedside Anastasio Ameijeiras Sibauste | Do not move this row to Santiago |
| Ethics | Institutional committee calendars at the host buildings | Packet, ICF, IB, CNBI-registered process covering both sites if both are on the file |
| National authority | Not the permit holder by appearing in an XCath wire | MINSA / CNBI |
| Import | Receiving and storage if contracted | Importer of record |
| Quality | Each building’s local quality and the case they physically ran | ISO 14155 monitoring, EDC, SAE, TMF |
| FDA conversation | Source documents from cases they run | 21 CFR 812.28 narrative — eligibility, not clearance |
| Country optionality | Two Panama buildings on one public story | Colombia (INVIMA) and the rest of the bioaccess® platform |
How MINSA and CNBI actually work (the short version)
Use clinical-trials-panama for the full pathway. Facts a sponsor searching Clínica Norte needs on one screen, already published there and not re-averaged here:
- Panama’s Ministry of Health (MINSA), through the Dirección Nacional de Farmacia y Drogas, is the national health authority on device investigations. Ethics runs through institutional bioethics committees registered with CNBI.
- On clinical-trials-panama: ethics typically 3–5 weeks; with bioaccess® coordination, protocol submission to first-patient enrollment averages 6–8 weeks. Per-patient costs on that page: $12,000–$22,000. Currency is the U.S. dollar.
- On the March 2026 blog: early-feasibility is ethics-committee-driven (no separate national device-authority step of the INVIMA/ANVISA type); CNBI often 4–8 weeks; conservative submission-to-first-patient envelope 3–5 months including site prep and screening.
- Under 21 CFR 812.28, foreign clinical data from Panama is eligible for FDA submission and review when studies are conducted under ISO 14155 with proper ethics documentation. Eligibility is not a guarantee of clearance or approval. See OUS FIH and FDA IDE.
Ask for a protocol-specific calendar. A clinic email from Santiago is not a MINSA approval. bioaccess® manages the submission. That is CRO work, not site work.
All bioaccess® Panama device protocols are run under ISO 14155 and the Declaration of Helsinki. Data is designed to be eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — not a guarantee of clearance or approval.
Do not smear either building — and do not invent Norte as the implant hospital
Clínica Norte and The Panama Clinic are serious clinical resources. Use the console site when the protocol needs a remote operator room. Use The Panama Clinic when the protocol needs that bedside hospital. Hire the operator for the file.
Do not assign the XCath patient to Clínica Norte. The NeuroNews rewrite places the patient at The Panama Clinic. Do not clone The Panama Clinic first-in-human. Do not add Nanochon on this page. Nanochon is HOLD as a client claim; its press names The Panama Clinic, not Norte.
What the CRO still does after you have a Norte slide
- Regulatory-fit, not tourism. Panama is fast and bilingual. A remote-console clinic in Santiago is not automatically the right room for every device indication. bioaccess® still runs trials in Colombia and the rest of the platform.
- Protocol, IB, ICF, insurance, and the MINSA/CNBI packet — written so a remote console and a bedside hospital are one investigation if both are on the file.
- Importer of record and device accountability.
- Site activation that is more than a tour: contracts, training, investigational product, EDC, monitoring plan. Activate Clínica Norte, The Panama Clinic, or both only if they fit the protocol. Do not activate Norte as the implant hospital if the protocol’s patient is elsewhere.
- ISO 14155 monitoring and the 21 CFR 812.28 narrative — eligibility, not a promise of FDA action.
The firm was founded in 2010. That is the operator layer around a press-named console site.
Colombia is still on the map
A site-name search sometimes arrives with a stale story that bioaccess® “left Colombia.” That is false. bioaccess® still runs clinical trials in Colombia. Always bioaccess® — local entity and office, Miami headquarters, INVIMA clocks in-country. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K as published on clinical-trials-panama. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.
Frequently asked questions
Was the XCath patient treated at Clínica Norte?
Not according to the public wires this page cites. NeuroNews places the patient at The Panama Clinic, Panama City, with the remote operator at Clínica Norte, Santiago. We will not invent Norte as the implant hospital.
Can I contract Clínica Norte directly for a device FIH?
You can try. The clinic can discuss a console room, investigator interest, and local costs. It cannot, by appearing in four XCath URLs, become your MINSA/CNBI applicant, importer of record, insurer, ISO 14155 monitor, or 21 CFR 812.28 packager. Contract the CRO, then let the CRO activate the right building for the right role.
Did bioaccess® run Operation Robo Angel / XCath?
No public bioaccess® case-study page names this program. We will not invent that claim. mention_n=4 is a press-URL count, not bioaccess® enrollment. Named bioaccess® FIH at The Panama Clinic remains Axoft and Newrotex on the live hospital intercept.
Next step
If the search that brought you here was Clínica Norte or XCath Panama, start as the operator: contact bioaccess® or book from First-in-Human CRO. Bedside hospital intercept: The Panama Clinic first-in-human. Country: clinical trials in Panama.
Julio G. Martinez-Clark, CEO · bioaccess®